Of interest, the number of Tie2+ cells was significantly greater in the brains of the animals with an invasive glioma phenotype (treated with aflibercept during 6 weeks or bevacizumab) than in those harboring non-invasive tumors (treated with vehicle, TMZ, or the short schedule of aflibercept) (Figure 1C, P < 0.001, aflibercept-6 weeks versus aflibercept-3 weeks). The gene discussed is TEK; the disease is central nervous system cancer.